Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy

Different stimuli can polarize macrophages into two basic types, M1 and M2. Tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) are composed of heterogeneous subpopulations, which include the M1 anti-tumor and M2 pro-tumor phenotypes. TAMs predominantly play a M2-like tumor-promo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in immunology Ročník 13; s. 888713
Hlavní autoři: Gao, Jing, Liang, Yuanzheng, Wang, Liang
Médium: Journal Article
Jazyk:angličtina
Vydáno: Frontiers Media S.A 30.06.2022
Témata:
cancer therapy
Immunology
polarization
signaling pathways
tumor microenvironment
tumor-associated macrophages
ISSN:1664-3224, 1664-3224
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Different stimuli can polarize macrophages into two basic types, M1 and M2. Tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) are composed of heterogeneous subpopulations, which include the M1 anti-tumor and M2 pro-tumor phenotypes. TAMs predominantly play a M2-like tumor-promoting role in the TME and regulate various malignant effects, such as angiogenesis, immune suppression, and tumor metastasis; hence, TAMs have emerged as a hot topic of research in cancer therapy. This review focuses on three main aspects of TAMs. First, we summarize macrophage polarization along with the effects on the TME. Second, recent advances and challenges in cancer treatment and the role of M2-like TAMs in immune checkpoint blockade and CAR-T cell therapy are emphasized. Finally, factors, such as signaling pathways, associated with TAM polarization and potential strategies for targeting TAM repolarization to the M1 pro-inflammatory phenotype for cancer therapy are discussed.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Sukh Mahendra Singh, Banaras Hindu University, India
Reviewed by: Naveen Kumar Vishvakarma, Guru Ghasidas Vishwavidyalaya, India; Santosh Kumar, National Institute of Technology Rourkela, India
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.888713